Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

• Status: Recruiting
• Trial end date: 2024-03-01

Summary

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients with controlled disease after 3 cycles (Part 1).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: GWT-TUD GmbH
• Collaborators: AstraZeneca; Celgene
• Treatments: Albumin-Bound Paclitaxel; Azacitidine; Durvalumab; Gemcitabine; Lenalidomide; Paclitaxel; Romidepsin